H
Hani Hassoun
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 214
Citations - 6827
Hani Hassoun is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Multiple myeloma & Lenalidomide. The author has an hindex of 36, co-authored 177 publications receiving 5953 citations. Previous affiliations of Hani Hassoun include McGill University & NewYork–Presbyterian Hospital.
Papers
More filters
Journal ArticleDOI
Lenalidomide after stem-cell transplantation for multiple myeloma
Philip L. McCarthy,Kouros Owzar,Craig C. Hofmeister,David D. Hurd,Hani Hassoun,Paul G. Richardson,Sergio Giralt,Edward A. Stadtmauer,Daniel J. Weisdorf,Ravi Vij,Jan S. Moreb,Natalie S. Callander,Koen van Besien,Teresa Gentile,Luis Isola,Richard T. Maziarz,Don A. Gabriel,Asad Bashey,Heather Landau,Thomas G. Martin,Muzaffar H. Qazilbash,Denise Levitan,Brian McClune,Robert L. Schlossman,Vera Hars,John Postiglione,Chen Jiang,Elizabeth Bennett,Susan Barry,Linda Bressler,Michael Kelly,Michele Seiler,Cara A. Rosenbaum,Parameswaran Hari,Marcelo C. Pasquini,Mary M. Horowitz,Thomas C. Shea,Steven M. Devine,Kenneth C. Anderson,Charles A. Linker +39 more
TL;DR: Lenalidomide maintenance therapy, initiated at day 100 after hematopoietic stem-cell transplantation, was associated with more toxicity and second cancers but a significantly longer time to disease progression and significantly improved overall survival among patients with myeloma.
Journal ArticleDOI
Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosyl-ceramide loaded mature dendritic cells in cancer patients
David H. Chang,Keren Osman,John Connolly,Anjli Kukreja,Joseph Krasovsky,Maggi Pack,Aisha Hutchinson,Matthew D. Geller,Nancy Liu,Rebecca Annable,Jennifer Shay,Kelly Kirchhoff,Nobusuke Nishi,Yoshitaka Ando,Kunihiko Hayashi,Hani Hassoun,Ralph M. Steinman,Madhav V. Dhodapkar,Madhav V. Dhodapkar +18 more
TL;DR: The feasibility of sustained expansion of NKT cells in vivo in humans, including patients who have advanced cancer, is demonstrated and it is suggested that NKT activation might help to boost adaptive T cell immunity in vivo.
Journal ArticleDOI
High Incidence of Thromboembolic Events in Patients Treated With Cisplatin-Based Chemotherapy: A Large Retrospective Analysis
Russell A. Moore,Nelly G. Adel,Elyn Riedel,Manisha Bhutani,Darren R. Feldman,Nour Elise Tabbara,Gerald A. Soff,Rekha Parameswaran,Hani Hassoun +8 more
TL;DR: A large retrospective analysis confirms the unacceptable incidence of TEEs in patients receiving cisplatin-based chemotherapy and calls for randomized studies to be urgently needed in this specific cancer population treated with cisplant-based regimens.
Journal ArticleDOI
Phase I Trial of Bevacizumab Plus Escalated Doses of Sunitinib in Patients With Metastatic Renal Cell Carcinoma
Darren R. Feldman,Michael Baum,Michelle S. Ginsberg,Hani Hassoun,Carlos D. Flombaum,Susanne Velasco,Patricia Fischer,Ellen A. Ronnen,Nicole Ishill,Sujata Patil,Robert J. Motzer +10 more
TL;DR: In this phase I trial of patients with metastatic RCC, the combination of sunitinib and bevacizumab caused a high degree of hypertension and vascular and hematologic toxicities at the highest dose level.
Journal ArticleDOI
Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications
David H. Chang,Nancy Liu,Nancy Liu,Virginia M. Klimek,Virginia M. Klimek,Hani Hassoun,Hani Hassoun,Amitabha Mazumder,Amitabha Mazumder,Stephen D. Nimer,Stephen D. Nimer,Sundar Jagannath,Sundar Jagannath,Madhav V. Dhodapkar,Madhav V. Dhodapkar +14 more
TL;DR: It is demonstrated that LEN and its analogues enhance CD1d-mediated presentation of glycolipid antigens and support combining these agents with NKT targeted approaches for protection against tumors.